Ebi3/IL-27 depleted microenvironment favors tumor progression in Chronic Lymphocytic Leukemia
Despite significant advances in the last decades, current treatment options for Chronic Lymphocytic Leukaemia (CLL) mainly aim to reduce the tumour burden and, unfortunately, do not represent a curative approach. Compelling evidence indicates that CLL development and progression are strongly dependent on signals from the tumour microenvironment (TME).
In recent years, several pro-inflammatory cytokines have emerged as a powerful tool to reactivate the immune system in a wide range of malignancies, alone or in combination with other immunotherapies. IL-27 is a member of the IL-12 family of heterodimeric cytokines shown to have pleiotropic functions during cancer development, promoting or hindering cancer progression depending on the tumoral context.
In this study, we extensively characterized the anti-tumoral role of IL-27 in the development and progression of CLL using a variety of in vivo and ex vivo approaches.